Tango Therapeutics (NASDAQ:TNGX) Price Target Raised to $68.00

Tango Therapeutics (NASDAQ:TNGX) had its price target raised by HC Wainwright from $66.00 to $68.00 in a research report sent to investors on Tuesday, Marketbeat.com reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Tango Therapeutics’ Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.34) EPS, Q1 2027 earnings at ($0.35) EPS, Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.41) EPS and FY2027 earnings at ($1.54) EPS.

A number of other research firms have also recently commented on TNGX. Wall Street Zen cut Tango Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. UBS Group set a $55.00 target price on Tango Therapeutics in a research report on Thursday, May 14th. Wedbush boosted their price target on Tango Therapeutics from $19.00 to $33.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. Weiss Ratings raised shares of Tango Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Piper Sandler cut shares of Tango Therapeutics from an “overweight” rating to a “neutral” rating and increased their price objective for the stock from $16.00 to $24.00 in a research note on Thursday, May 14th. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $43.46.

Tango Therapeutics Trading Down 6.7%

NASDAQ:TNGX opened at $23.51 on Tuesday. The company has a market cap of $3.96 billion, a PE ratio of -27.66 and a beta of 1.16. The company has a 50 day simple moving average of $28.49 and a two-hundred day simple moving average of $22.69. Tango Therapeutics has a 12 month low of $6.25 and a 12 month high of $34.39.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.05). Research analysts forecast that Tango Therapeutics will post -1.38 earnings per share for the current year.

Insider Activity at Tango Therapeutics

In related news, insider Adam Crystal sold 27,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total value of $798,930.00. Following the transaction, the insider directly owned 115,743 shares of the company’s stock, valued at approximately $3,424,835.37. This trade represents a 18.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.50% of the stock is owned by company insiders.

Institutional Trading of Tango Therapeutics

Several hedge funds have recently bought and sold shares of TNGX. Allworth Financial LP bought a new stake in Tango Therapeutics during the 2nd quarter worth approximately $35,000. Global Retirement Partners LLC bought a new position in shares of Tango Therapeutics in the fourth quarter worth approximately $35,000. Dynamic Technology Lab Private Ltd boosted its position in shares of Tango Therapeutics by 139.7% in the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock worth $35,000 after purchasing an additional 15,037 shares during the period. Legal & General Group Plc increased its stake in shares of Tango Therapeutics by 30.7% in the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after purchasing an additional 1,640 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in shares of Tango Therapeutics in the fourth quarter worth $40,000. Institutional investors own 78.99% of the company’s stock.

Trending Headlines about Tango Therapeutics

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and set a $68 price target, reflecting substantial confidence in Tango’s longer-term potential despite near-term losses. HC Wainwright Increases Tango Therapeutics Price Target to $68
• Neutral Sentiment: The analyst expects Tango to remain unprofitable through 2027, forecasting full-year 2027 EPS of ($1.54), with quarterly losses ranging from ($0.37) to ($0.41). These estimates underscore the company’s continued dependence on clinical and pipeline progress rather than current earnings.
• Negative Sentiment: HC Wainwright reduced its 2026 EPS forecasts to ($0.32) from ($0.26) for the third quarter, to ($0.34) from ($0.27) for the fourth quarter, and to ($1.34) from ($1.15) for the full year. The estimate cuts suggest weaker near-term financial performance and likely contributed to the stock’s decline.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.